No Data
No Data
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development
Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
Buy Rating Justified by Aprea Therapeutics' Financial Health and Innovative Clinical Trials
Wedbush Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $11
No Data
No Data